After Biogen failed with a takeover bid in January, Supernus has swooped in to buy the postpartum depression pill developer.

MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

Surovatamig shows promise, but needs to outperform established therapies such as Blincyto and Aucatzyl.

Ethris has entered a strategic partnership with Thermo Fisher Scientific for providing completely integrated mRNA solution.

NHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.

Lynozyfic’s global sales are projected to reach $707 million by 2031.

MSD has received FDA approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) in neonates and ...

The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir).

GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and ...

Geopolitical disturbances across the supply chain are further complicating the complex pharma customs process.